Compare Adaptive Biotechnologies Corp (ADPT) vs Tidewater Inc (TDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Tidewater Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Tidewater Inc trades at $72.26 (market cap $3.54B). The key difference: Adaptive Biotechnologies Corp and Tidewater Inc are close in size by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | TDW | |
|---|---|---|
Market Cap | $3.33B | $3.54B |
Sector | Health | Utilities |
52-Week High | $22.37 | $91.12 |
52-Week Low | $10.24 | $46.32 |
Enterprise Value | $3.19B | $3.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Tidewater (TDW) trades at $68.19, up 0.1% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. Recent earnings misses in Q1 2026 and Q4 2025 contrast with strong 2025 profitability, including a 22.16% net income margin and 24.03% ROE. The company reported $1.35B revenue in 2025, with net income of $334.66M, though 2026 projections indicate a slight decline. Positive cash flow from operations of $379.11M in 2025 supports financial health, while analyst sentiment remains cautious with a 'Hold' consensus.
Outlook: TDW's valuation appears reasonable with a P/E of 11.5 and EV/EBITDA of 8.52, but recent earnings volatility and a 61.54% analyst hold rating suggest near-term headwinds. Key risks include execution challenges amid declining revenue projections and competitive pressures in offshore marine services. Upside potential hinges on improved earnings consistency and sector recovery, while downside risks involve further profit margin compression and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
